Cargando…
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
BACKGROUND: Immunotherapy is being tested in early‐stage non‐small cell lung cancer (NSCLC), and achieving higher rates of complete pathological responses (CPR) as compared to standard of care. Early identification of CPR patients has vital clinical implications. In this study, we focused on basal p...
Autores principales: | Laza‐Briviesca, Raquel, Cruz‐Bermúdez, Alberto, Nadal, Ernest, Insa, Amelia, García‐Campelo, María del Rosario, Huidobro, Gerardo, Dómine, Manuel, Majem, Margarita, Rodríguez‐Abreu, Delvys, Martínez‐Martí, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Massuti, Bartomeu, Casarrubios, Marta, Sierra‐Rodero, Belén, Tarín, Carlos, García‐Grande, Aránzazu, Haymaker, Cara, Wistuba, Ignacio I., Romero, Atocha, Franco, Fernando, Provencio, Mariano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288017/ https://www.ncbi.nlm.nih.gov/pubmed/34323406 http://dx.doi.org/10.1002/ctm2.491 |
Ejemplares similares
-
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
por: Sierra-Rodero, Belén, et al.
Publicado: (2021) -
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021) -
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
por: Provencio, Mariano, et al.
Publicado: (2022) -
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022) -
The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy
por: Cruz-Bermúdez, Alberto, et al.
Publicado: (2021)